Endometrial carcinoma

This study tested whether a combination of three drugs—everolimus, letrozole, and metformin—can help control advanced or recurrent endometrial cancer. The 62 participants had cancer that came back or spread and had limited prior treatments. The goal was to see how many patients h…

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This phase II trial tests whether combining two hormone-blocking drugs — onapristone and anastrozole — can shrink tumors or slow cancer growth in women with hormone-receptor-positive endometrial cancer that has not responded to prior chemotherapy. Onapristone blocks progesterone …

This phase II trial tests whether the drug RAD001 can shrink or slow the growth of tumors in people with recurrent endometrial cancer. Participants take RAD001 daily by mouth. The study measures how many patients have their tumors shrink or stay stable, and also tracks side effec…

This study looks at whether a ketogenic diet—a very low-carbohydrate diet that forces the body to burn fat for energy—is safe and tolerable for overweight or obese women with newly diagnosed endometrial cancer before they have surgery. Nineteen participants will either follow the…

This phase 2 study tested a drug called retifanlimab, which helps the immune system attack cancer, either alone or combined with other targeted drugs. It enrolled 206 women with advanced or metastatic endometrial cancer that had worsened after platinum-based chemotherapy. The goa…

This early-phase trial tested a combination of three drugs—olaparib, metformin, and cyclophosphamide—in 35 women with recurrent advanced endometrial cancer that had already been treated with chemotherapy. The goal was to find a safe dose and see if the combination could stop the …

This study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before s…

This phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…

This phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer'…

This study tested whether the drug rucaparib can help keep metastatic or recurrent endometrial cancer from growing. 79 women who had already received chemotherapy took either rucaparib or a placebo pill twice daily. The goal was to see if rucaparib could delay cancer progression …

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …

This phase 2 study tested a combination of two drugs, fulvestrant and abemaciclib, in 28 patients with a specific type of uterine cancer that is sensitive to hormones. The goal was to see if the drugs could shrink tumors or stop them from growing. Researchers also tracked side ef…

This phase 3 study tested whether combining the immunotherapy pembrolizumab with the targeted therapy lenvatinib works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. Over 800 participants received either the drug combo or chemo. The goa…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, against standard chemotherapy for women with advanced or recurrent endometrial cancer. The goal was to see if the combo could slow cancer growth or improve survival better than chemo. The trial enrolled 1…

This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any …

This study tested whether oliceridine, a newer painkiller, is as safe and effective as the standard drug sufentanil for putting patients to sleep before gynecologic laparoscopic surgery. 120 women with endometrial cancer took part. Researchers monitored blood pressure and heart r…

This phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while s…

This observational study will examine the molecular and epidemiological characteristics of endometrial cancer in Brazil, focusing on women diagnosed between 2016 and 2019. Researchers will analyze tumor samples for genetic mutations and biomarkers, and collect data on demographic…

This study looked at 150 women with intermediate- or high-risk endometrial cancer who had surgery to remove the uterus and nearby lymph nodes. Researchers compared removing lymph nodes up to a higher level (near the kidney) versus a lower level (near the pelvis) to see which appr…

This completed study looked at how muscle energy use differs in women with ovarian or endometrial cancer who are losing weight, depending on their body mass index (BMI). Researchers took blood samples, muscle biopsies, and fat tissue from 70 women during surgery. The goal was to …

This study looked at medical records from 509 adults in Taiwan to find out how often advanced cervical, endometrial, and ovarian cancers have a specific marker called HER2 IHC 3+. Researchers also described the patients' health details to better understand who might benefit from …

This study tested over 1,000 women with endometrial cancer for DNA repair problems that can be inherited (Lynch syndrome). By analyzing tumor DNA, researchers aimed to personalize cancer treatment and identify family members who might also be at risk. The goal was to improve care…